[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][O][C][=C][Branch2][Ring2][=N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][N][C][=N][C][=Branch2][Ring1][Ring2][=N][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][C][C][=N][C][=C][C][=N][Ring1][=Branch1][N][C][C][C][C@H1][Ring1][Branch1][C][O][Cl]"}, {"from": "gpt", "value": "The molecule is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition.  It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013."}]